Physician profile
Christopher Sweeney
NPI 1639135965
$3,478.99
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $254 · 2021: $741 · 2022: $769 · 2023: $946 · 2024: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $871.71 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $522.47 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $492.66 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $321.64 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $174.51 | 2019-2023 | Farxiga |
| Amgen INC. | $150.49 | 2019-2022 | |
| Glaxosmithkline, LLC. | $117.59 | 2019-2023 | Shingrix |
| Exact Sciences Corporation | $106.21 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $89.33 | 2019-2023 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $76.45 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $68.69 | 2019-2020 | |
| Ethicon INC. | $65.87 | 2023 | Monarch Platform |
| Bayer Healthcare Pharmaceuticals INC. | $55.12 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $47.41 | 2022-2023 | Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.31 | 2021-2023 | Jardiance, Synjardy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $29.53 | 2020 | |
| Dexcom, INC. | $28.84 | 2022-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $27.64 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $27.20 | 2021 | |
| Lilly USA, LLC | $26.54 | 2019-2022 | |
| Amarin Pharma, INC. | $25.44 | 2019 | |
| Edwards Lifesciences Corporation | $24.20 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.78 | 2019-2021 | |
| Inspire Medical Systems, INC. | $21.66 | 2023 | Inspire |
| Allergan, INC. | $14.91 | 2020 | |
| Axonics, INC. | $14.28 | 2023 | Axonics |
| Sanofi Pasteur INC. | $13.47 | 2019 | |
| Dynavax Technologies Corporation | $10.04 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.